Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Background/Aims: To investigate pre-existing hepatitis B virus (HBV) quasispecies and the genotypic evolution of several variants. Methods: From six patients with lamivudine (LAM) failure, serum samples at pretreatment, 6 months of LAM therapy, and virologic breakthrough were obtained. One hundred clones with HBV inserts in each patient were sequenced at each time point. Pretreatment serum samples were also analyzed from six patients who achieved good responses to LAM therapy. Results: Among the six patients with LAM failure, the analysis of 100 clones from patient 1revealed the substitutions L180M in 1% of clones and V173L in 2% of clones. Patient 2 had substitutions of L80V, W153Q,and L180M. In patient 3, mutations conferring resistance to adefovir at V84I (5%), I169L (1%), and N236H (7%) and entecavir at S202G (2%) were detected. Patient 4 had mutations at T128N (1%), I169L (1%), V173L (2%), A181V (1%),and Q215H (1%). In patient 5, M204V/I was detected in 1%and 2% of clones, respectively. L80I and V173L were also identified in patient 6. In the six patients who responded to LAM, the degree of overall quasispecies was less than those with LAM failure. Conclusions: Various HBV quasispecies associated with drug resistance existed before treatment, and the quasispecies dynamically changed through LAM therapy
Abstract
Background/Aims: To investigate pre-existing hepatitis B virus (HBV) quasispecies and the genotypic evolution of several variants. Methods: From six patients with lamivudine (LAM) failure, serum samples at pretreatment, 6 months of LAM therapy, and virologic breakthrough were obtained. One hundred clones with HBV inserts in each patient were sequenced at each time point. Pretreatment serum samples were also analyzed from six patients who achieved good responses to LAM therapy. Results: Among the six patients with LAM failure, the analysis of 100 clones from patient 1revealed the substitutions L180M in 1% of clones and V173L in 2% of clones. Patient 2 had substitutions of L80V, W153Q,and L180M. In patient 3, mutations conferring resistance to adefovir at V84I (5%), I169L (1%), and N236H (7%) and entecavir at S202G (2%) were detected. Patient 4 had mutations at T128N (1%), I169L (1%), V173L (2%), A181V (1%),and Q215H (1%). In patient 5, M204V/I was detected in 1%and 2% of clones, respectively. L80I and V173L were also identified in patient 6. In the six patients who responded to LAM, the degree of overall quasispecies was less than those with LAM failure. Conclusions: Various HBV quasispecies associated with drug resistance existed before treatment, and the quasispecies dynamically changed through LAM therapy
참고문헌 (23)
- Hollinger FB, "Hepatitis B virus genetic diversity and its impact on diagnostic assays", J Viral Hepat, 14(Suppl 1), pp.11~15 (2007)
- Cane PA, "Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation", Antivir Ther, 4, pp.7~14 (1999)
- Lai CL, "A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group", N Engl J Med, 339, pp.61~68 (1998)
- Dienstag JL, "Lamivudine as initial treatment for chronic hepatitis B in the United States", N Engl J Med, 341, pp.1256~1263 (1999)
- Yuen MF, "Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease", Antivir Ther, 12, pp.1295~1303 (2007)
- Xiong X, "In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance", Hepatology, 31, pp.219~224 (2000)
- Dienstag JL, "Durability of serologic response after lamivudine treatment of chronic hepatitis B", Hepatology, 37, pp.748~755 (2003)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Lai CL, "Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection", Gastroenterology, 123, pp.1831~1838 (2002)
- Colonno RJ, "Entecavir resistance is rare in nucleoside naive patients with hepatitis B", Hepatology, 44, pp.1656~1665 (2006)
- Bartholomeusz A, "Antiviral drug resistance: clinical consequences and molecular aspects", Semin Liver Dis, 26, pp.162~170 (2006)
- Tenney DJ, "Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present", Antimicrob Agents Chemother, 51, pp.902~911 (2007)
- Lok AS, "Chronic hepatitis B", Hepatology, 45, pp.507~539 (2007)
- Bartholomeusz A, "Hepatitis B virus mutations associated with antiviral therapy", J Med Virol, (78 Suppl 1), pp.S52~S55 (2006)
- Kobayashi S, "Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers", J Hepatol, 34, pp.584~586 (2001)
- Jardi R, "Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients", J Viral Hepat, 14, pp.835~840 (2007)
- Mirandola S, "Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B", J Viral Hepat, 18, pp.e212~e216 (2011)
- Yim HJ, "Evolution of multi-drug resistant hepatitis B virus during sequential therapy", Hepatology, 44, pp.703~712 (2006)
- Moriconi F, "Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment", J Antimicrob Chemother, 60, pp.341~349 (2007)
- Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine", Antimicrob Agents Chemother, 48, pp.3498~3507 (2004)
- Guo JJ, "Dynamics of hepatitis B virus resistance to entecavir in a nucleoside", nucleotide-naive patient, 2009, pp.81, 180~183